Although the combination of anti-PD-1/PD-L1 and anti-CTLA-4 agents has demonstrated superior efficacy over monotherapy in multiple tumor types, its clinical benefits in specific malignancies such as HNSCC require further precise delineation. Here, CTLA4 is linked to head and neck squamous cell carcinoma.